Published Date: 08 Mar 2023
Results from the RESCUE BT2 trial showed that among patients with mild or major strokes, more patients taking tirofiban had better 90-day outcomes than aspirin.
Read Full NewsIrreversible nerve damage to the lower limbs is a common side effect of chemotherapy, yet up to 50% of patients are missing out on vital foot care that could significantly ease their symptoms, according to new research from ...
A new University of California San Diego study offers compelling evidence that glucagon-like peptide-1 (GLP-1) receptor agonists—the class of drugs behind Ozempic, Wegovy and Mounjaro, for example—may do more than regulate ...
Lung cancer remains the leading cause of cancer death in the U.S., responsible for about 1 in 4, but major advances in screening, surgery and personalized treatment are helping more patients live longer.
1.
What Role Should Genomic Classifier Testing Play in Prostate Cancer?
2.
Effects of Recombinant Replacement Therapy Explained in Detailed Regarding Genetic Clotting Disorder.
3.
In Acute Myeloid Leukemia Diagnosed Recently, FLT3 Inhibitor Is Very Effective.
4.
Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular Lymphoma
5.
Study: Elinzanetant cuts vasomotor symptoms in women with breast cancer on endocrine therapy
1.
Unlocking Immunity: TILs, Immunotherapy Biomarkers, and Toxicity Management in Oncology
2.
A New Hope: Exploring Treatment Options for Waldenstrom's Macroglobulinemia
3.
Next-Gen CAR Cell Therapies in Oncology: Frontiers in Solid Tumors & Hematologic Malignancies
4.
Managing Hematoma: A Guide to Prevention and Treatment
5.
Tremelimumab: A Potential Breakthrough in Cancer Treatment
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Navigating the Complexities of Ph Negative ALL - Part XII
2.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII
3.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- Further Discussion
4.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VI
5.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation